Shire has announced the launch of Xiidra (lifitegrast ophthalmic solution) 5%, the first prescription treatment for both the signs and symptoms of dry eye disease. The Food and Drug Administration (FDA) approved Xiidra on July 11, 2016.  

Xiidra is a first-in-class lymphocyte function-associated antigen-1 (LFA-1) antagonist. The exact mechanism of action of lifitegrast in dry eye disease is not known. Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. 

Related Articles

Xiidra comes in a foil pouch containing five low density polyethylene 0.2mL single-use containers and will be packaged in a carton of 60 single use containers. 

For more information visit